Comparative Pharmacology
Head-to-head clinical analysis: FLORONE versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLORONE versus KENALOG IN ORABASE.
FLORONE vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; induces phospholipase A2 inhibitory proteins (lipocortins), which suppress release of arachidonic acid and subsequent prostaglandin/leukotriene synthesis; also suppresses cytokine production and immune cell migration.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum use: 45 g/week.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Terminal elimination half-life of approximately 2-3 hours; clinical context: duration of action may extend beyond half-life due to tissue binding.
Terminal half-life approximately 2-5 hours following mucosal application.
Renal (approximately 80% as metabolites, <5% unchanged), biliary/fecal (remainder).
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid